Does the media favor RVTY or ADPT?

In the previous week, Revvity had 14 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 21 mentions for Revvity and 7 mentions for Adaptive Biotechnologies. Revvity's average media sentiment score of 0.85 beat Adaptive Biotechnologies' score of 0.85 indicating that Revvity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revvity 7 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ICLR or ADPT?

In the previous week, Icon had 3 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 10 mentions for Icon and 7 mentions for Adaptive Biotechnologies. Icon's average media sentiment score of 1.05 beat Adaptive Biotechnologies' score of 0.85 indicating that Icon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Icon 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TECH or ADPT?

In the previous week, Adaptive Biotechnologies had 1 more articles in the media than Bio-Techne. MarketBeat recorded 7 mentions for Adaptive Biotechnologies and 6 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.37 beat Adaptive Biotechnologies' score of 0.85 indicating that Bio-Techne is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BRKR or ADPT?

In the previous week, Bruker had 14 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 21 mentions for Bruker and 7 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 0.85 beat Bruker's score of 0.85 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bruker 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Adaptive Biotechnologies (ADPT) Competitors

$24.93 +1.33 (+5.64%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$24.76 -0.16 (-0.66%)

As of 08/7/2026 07:45 PM Eastern

Compare

ADPT vs. RVTY, ICLR, TECH, CRL, and BRKR

Should you buy Adaptive Biotechnologies stock or one of its competitors? MarketBeat compares Adaptive Biotechnologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adaptive Biotechnologies include Revvity (RVTY), Icon (ICLR), Bio-Techne (TECH), Charles River Laboratories International (CRL), and Bruker (BRKR). These companies are all part of the "life sciences tools & services" industry.

How does Adaptive Biotechnologies compare to Revvity?

Revvity (NYSE:RVTY) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

In the previous week, Revvity had 14 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 21 mentions for Revvity and 7 mentions for Adaptive Biotechnologies. Revvity's average media sentiment score of 0.85 beat Adaptive Biotechnologies' score of 0.85 indicating that Revvity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revvity	7 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revvity has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market.

Revvity has a net margin of 8.16% compared to Adaptive Biotechnologies' net margin of -20.73%. Revvity's return on equity of 8.34% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revvity	8.16%	8.34%	5.01%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

Revvity currently has a consensus target price of $108.36, suggesting a potential downside of 5.61%. Adaptive Biotechnologies has a consensus target price of $24.42, suggesting a potential downside of 2.06%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, analysts plainly believe Adaptive Biotechnologies is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	0 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Revvity has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.86B	4.48	$241.20M	$2.10	54.67
Adaptive Biotechnologies	$308.08M	12.91	-$59.50M	-$0.41	N/A

86.7% of Revvity shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 0.9% of Revvity shares are held by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Revvity beats Adaptive Biotechnologies on 9 of the 16 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Icon?

Icon (NASDAQ:ICLR) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Icon had 3 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 10 mentions for Icon and 7 mentions for Adaptive Biotechnologies. Icon's average media sentiment score of 1.05 beat Adaptive Biotechnologies' score of 0.85 indicating that Icon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Icon	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Icon presently has a consensus price target of $170.40, indicating a potential upside of 3.58%. Adaptive Biotechnologies has a consensus price target of $24.42, indicating a potential downside of 2.06%. Given Icon's higher probable upside, analysts plainly believe Icon is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Icon	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.41
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Icon has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market.

Icon has a net margin of 3.99% compared to Adaptive Biotechnologies' net margin of -20.73%. Icon's return on equity of 8.02% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Icon	3.99%	8.02%	4.56%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

95.6% of Icon shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 44.0% of Icon shares are owned by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Icon has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Icon	$8.29B	1.52	$229.34M	$4.26	38.62
Adaptive Biotechnologies	$308.08M	12.91	-$59.50M	-$0.41	N/A

Summary

Icon beats Adaptive Biotechnologies on 13 of the 17 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Bio-Techne?

Bio-Techne (NASDAQ:TECH) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Bio-Techne has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.28	$73.40M	$0.69	104.77
Adaptive Biotechnologies	$308.08M	12.91	-$59.50M	-$0.41	N/A

Bio-Techne has a net margin of 9.05% compared to Adaptive Biotechnologies' net margin of -20.73%. Bio-Techne's return on equity of 13.57% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	9.05%	13.57%	10.66%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

Bio-Techne currently has a consensus target price of $68.08, indicating a potential downside of 5.83%. Adaptive Biotechnologies has a consensus target price of $24.42, indicating a potential downside of 2.06%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, analysts clearly believe Adaptive Biotechnologies is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	1 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.12
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Bio-Techne has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market.

99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Adaptive Biotechnologies had 1 more articles in the media than Bio-Techne. MarketBeat recorded 7 mentions for Adaptive Biotechnologies and 6 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.37 beat Adaptive Biotechnologies' score of 0.85 indicating that Bio-Techne is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bio-Techne and Adaptive Biotechnologies tied by winning 8 of the 16 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Charles River Laboratories International?

Adaptive Biotechnologies (NASDAQ:ADPT) and Charles River Laboratories International (NYSE:CRL) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Adaptive Biotechnologies has higher earnings, but lower revenue than Charles River Laboratories International. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$308.08M	12.91	-$59.50M	-$0.41	N/A
Charles River Laboratories International	$4.00B	3.19	-$144.34M	-$4.85	N/A

Adaptive Biotechnologies has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

In the previous week, Charles River Laboratories International had 20 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 27 mentions for Charles River Laboratories International and 7 mentions for Adaptive Biotechnologies. Charles River Laboratories International's average media sentiment score of 0.96 beat Adaptive Biotechnologies' score of 0.85 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Charles River Laboratories International	14 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adaptive Biotechnologies presently has a consensus price target of $24.42, indicating a potential downside of 2.06%. Charles River Laboratories International has a consensus price target of $246.69, indicating a potential downside of 7.59%. Given Adaptive Biotechnologies' higher possible upside, equities research analysts clearly believe Adaptive Biotechnologies is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

Charles River Laboratories International has a net margin of -5.96% compared to Adaptive Biotechnologies' net margin of -20.73%. Charles River Laboratories International's return on equity of 15.75% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
Charles River Laboratories International	-5.96%	15.75%	6.51%

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Charles River Laboratories International beats Adaptive Biotechnologies on 9 of the 16 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Bruker?

Bruker (NASDAQ:BRKR) and Adaptive Biotechnologies (NASDAQ:ADPT) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Bruker has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market.

Bruker has a net margin of -2.35% compared to Adaptive Biotechnologies' net margin of -20.73%. Bruker's return on equity of 12.47% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bruker	-2.35%	12.47%	4.91%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

Bruker has higher revenue and earnings than Adaptive Biotechnologies. Bruker is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bruker	$3.44B	2.37	-$8.60M	-$0.70	N/A
Adaptive Biotechnologies	$308.08M	12.91	-$59.50M	-$0.41	N/A

79.5% of Bruker shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 27.2% of Bruker shares are owned by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Bruker presently has a consensus target price of $56.64, indicating a potential upside of 6.05%. Adaptive Biotechnologies has a consensus target price of $24.42, indicating a potential downside of 2.06%. Given Bruker's higher probable upside, equities analysts plainly believe Bruker is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bruker	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.57
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Bruker had 14 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 21 mentions for Bruker and 7 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 0.85 beat Bruker's score of 0.85 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bruker	7 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bruker beats Adaptive Biotechnologies on 10 of the 16 factors compared between the two stocks.

Get Adaptive Biotechnologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADPT vs. The Competition

Export

Metric	Adaptive Biotechnologies	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.98B	$9.57B	$7.01B	$13.00B
Dividend Yield	N/A	1.46%	2.58%	10.20%
P/E Ratio	-60.80	63.07	271.11	25.19
Price / Sales	12.91	263.54	595.59	79.93
Price / Cash	N/A	26.16	71.81	50.72
Price / Book	26.52	38.45	13.25	6.22
Net Income	-$59.50M	$56.66B	$3.45B	$342.66M
7 Day Performance	10.46%	5.17%	4.67%	4.41%
1 Month Performance	14.36%	0.37%	-1.28%	-1.10%
1 Year Performance	104.34%	22.07%	77.33%	23.99%

Adaptive Biotechnologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADPT Adaptive Biotechnologies	1.5072 of 5 stars	$24.93 +5.6%	$24.42 -2.1%	+104.3%	$3.98B	$308.08M	N/A	790	Analyst Forecast Gap Up
RVTY Revvity	2.8312 of 5 stars	$115.21 +2.4%	$108.36 -5.9%	+32.0%	$12.55B	$2.86B	55.12	11,000	Earnings Report Dividend Announcement Analyst Upgrade
ICLR Icon	3.2183 of 5 stars	$158.41 -3.2%	$170.40 +7.6%	+3.8%	$12.52B	$8.25B	37.19	40,100	Positive News
TECH Bio-Techne	2.7153 of 5 stars	$72.14 +0.1%	$68.08 -5.6%	+43.4%	$11.29B	$1.22B	104.55	3,100	Positive News Upcoming Earnings Analyst Forecast
CRL Charles River Laboratories International	2.8097 of 5 stars	$230.58 -0.8%	$220.75 -4.3%	+79.1%	$11.20B	$4.02B	N/A	19,700	News Coverage Earnings Report Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADPT) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adaptive Biotechnologies (ADPT) Competitors

ADPT vs. RVTY, ICLR, TECH, CRL, and BRKR

How does Adaptive Biotechnologies compare to Revvity?

Summary

How does Adaptive Biotechnologies compare to Icon?

Summary

How does Adaptive Biotechnologies compare to Bio-Techne?

Summary

How does Adaptive Biotechnologies compare to Charles River Laboratories International?

Summary

How does Adaptive Biotechnologies compare to Bruker?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADPT vs. The Competition

Adaptive Biotechnologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adaptive Biotechnologies (ADPT) Competitors

ADPT vs. RVTY, ICLR, TECH, CRL, and BRKR

How does Adaptive Biotechnologies compare to Revvity?

Does the media favor RVTY or ADPT?

Which has more volatility and risk, RVTY or ADPT?

Is RVTY or ADPT more profitable?

Do analysts prefer RVTY or ADPT?

Which has preferable earnings and valuation, RVTY or ADPT?

Do insiders and institutionals have more ownership in RVTY or ADPT?

Summary

How does Adaptive Biotechnologies compare to Icon?

Does the media refer more to ICLR or ADPT?

Do analysts rate ICLR or ADPT?

Which has more volatility & risk, ICLR or ADPT?

Is ICLR or ADPT more profitable?

Do insiders & institutionals believe in ICLR or ADPT?

Which has better earnings and valuation, ICLR or ADPT?

Summary

How does Adaptive Biotechnologies compare to Bio-Techne?

Which has higher valuation and earnings, TECH or ADPT?

Is TECH or ADPT more profitable?

Do analysts rate TECH or ADPT?

Which has more risk and volatility, TECH or ADPT?

Do institutionals and insiders believe in TECH or ADPT?

Does the media refer more to TECH or ADPT?

Summary

How does Adaptive Biotechnologies compare to Charles River Laboratories International?

Which has stronger earnings and valuation, ADPT or CRL?

Which has more volatility & risk, ADPT or CRL?

Does the media prefer ADPT or CRL?

Do analysts recommend ADPT or CRL?

Is ADPT or CRL more profitable?

Do institutionals & insiders believe in ADPT or CRL?

Summary

How does Adaptive Biotechnologies compare to Bruker?

Which has more volatility and risk, BRKR or ADPT?

Is BRKR or ADPT more profitable?

Which has preferable valuation and earnings, BRKR or ADPT?

Do institutionals and insiders believe in BRKR or ADPT?

Do analysts prefer BRKR or ADPT?

Does the media refer more to BRKR or ADPT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADPT vs. The Competition

Adaptive Biotechnologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools